Bio-Rad Laboratories stock analysis
Want to see BIO full AI Analyst Report?
Bio-Rad Laboratories (BIO) Stock Price & Analysis
BIO Stock Chart & Stats
- Day’s Range
- $364.11 - $373.50
- 52-Week Range
- $236.73 - $396.23
- Previous Close
- $370.48
- Volume
- N/A
- Average Volume (3M)
- 244.60K
- Market Cap
- $9.86B
- Enterprise Value
- $9.87B
- Total Cash (Recent Filing)
- $1.66B
- Total Debt (Recent Filing)
- $1.36B
- Price to Earnings (P/E)
- 9.6
- Beta
- 0.81
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- 2.83
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Bio-Rad’s low leverage and substantial equity base provide financial resilience and reduce refinancing risk. This structure gives management flexibility to continue investing in innovation, support operations through uneven demand, and pursue measured acquisitions without relying heavily on additional debt.
Diagnostics And DdPCR Momentum
Growth in Clinical Diagnostics and strong ddPCR instrument adoption show that Bio-Rad retains competitive product momentum in important workflows. Installed instruments can support recurring reagent and consumable demand, while portfolio expansion and workflow improvements may extend adoption over multiple quarters.
Margin And Cash-improvement Program
Reaffirmed cash-flow guidance and planned restructuring savings support a durable improvement in operating efficiency. If execution continues, lower costs and better productivity should strengthen cash generation and create additional capacity for innovation, portfolio development, and disciplined capital allocation.
Bears Say
Weak Revenue Outlook
The outlook indicates that overall demand remains fragile, particularly in Life Science, limiting near-term revenue visibility and operating leverage. Negative-to-flat growth also makes it harder to absorb fixed costs, sustain margin expansion, and build confidence that the recovery will persist.
China Pricing And Regulatory Pressure
China’s preference for domestic suppliers and updated reimbursement-related guidelines create a structural pricing and revenue headwind in in-vitro diagnostics. These pressures can reduce realized pricing, constrain customer demand, and make future growth less predictable in an important regional market.
Earnings Volatility And Charges
Large swings between losses and profits reduce confidence in the durability of Bio-Rad’s earnings power, even with a recent rebound. Inconsistent operating profitability can complicate planning, weaken returns on the capital base, and leave results more exposed to changes in demand and restructuring activity.
Bio-Rad Laboratories News
BIO FAQ
What was Bio-Rad Laboratories’s price range in the past 12 months?
What is Bio-Rad Laboratories’s market cap?
When is Bio-Rad Laboratories’s upcoming earnings report date?
How were Bio-Rad Laboratories’s earnings last quarter?
Is Bio-Rad Laboratories overvalued?
Does Bio-Rad Laboratories pay dividends?
What is Bio-Rad Laboratories’s EPS estimate?
How many shares outstanding does Bio-Rad Laboratories have?
What happened to Bio-Rad Laboratories’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Bio-Rad Laboratories?
What is the TipRanks Smart Score and how is it calculated?
Bio-Rad Laboratories Stock Smart Score
Company Description
Bio-Rad Laboratories
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz
- Employees
- 7,450
- Website
- www.bio-rad.com
- Address
- 1000 Alfred Nobel Drive, Hercules, CA, 94547, US
Bio-Rad Laboratories (BIO) Earnings & Revenues
BIO Company Deck
BIO Earnings Call
Earnings Call SentimentNeutral
The call conveyed cautious optimism. Bio-Rad highlighted a return to modest currency-neutral revenue growth, improving non-GAAP margins, strong ddPCR instrumentation, Diagnostics growth, product launches and ongoing restructuring and innovation initiatives. However, these positives were offset by declining total Life Science revenue, weak academic and government funding, China pricing pressure, logistics disruption, an expected fourth-quarter margin decline, negative-to-flat full-year revenue guidance and GAAP losses driven by restructuring and impairment charges. Management expects positive but not fully normalized growth in 2027.
View all BIO earnings summariesBIO Net sales Breakdown
- 39.53% Life Science
- 60.47% Clinical Diagnostics
- 0.00% Other Operations
BIO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 5 | 10 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 4 | 0 | 8 |












